Excess Body Fatness during Early to Mid-Adulthood and Survival from Colorectal and Breast Cancer: A Pooled Analysis of Five International Cohort Studies.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
31
05
2021
revised:
16
09
2021
accepted:
03
11
2021
pubmed:
17
11
2021
medline:
26
2
2022
entrez:
16
11
2021
Statut:
ppublish
Résumé
Here, we explore the association between excess weight during early to mid-adulthood and survival in patients diagnosed with breast and colorectal cancer, using a pooled analysis of five cohort studies and study participants from 11 countries. Participant-level body mass index (BMI) trajectories were estimated by fitting a growth curve model using over 2 million repeated BMI measurements from close to 600,000 cohort participants. Cumulative measures of excess weight were derived. Data from over 23,000 patients with breast and colorectal cancer were subsequently analyzed using time-to-event models for death with the date of diagnosis as start of follow-up. Study-specific results were combined through a random effect meta-analysis. We found a significant dose-response relationship ( Excess body fatness during early to mid-adulthood is associated not only with an increased risk of developing cancer, but also with a lower survival in patients with breast cancer. Our results emphasize the importance of public health policies aimed at reducing overweight during adulthood and inform future studies on the relationship between excess weight and cancer outcomes.
Sections du résumé
BACKGROUND
Here, we explore the association between excess weight during early to mid-adulthood and survival in patients diagnosed with breast and colorectal cancer, using a pooled analysis of five cohort studies and study participants from 11 countries.
METHODS
Participant-level body mass index (BMI) trajectories were estimated by fitting a growth curve model using over 2 million repeated BMI measurements from close to 600,000 cohort participants. Cumulative measures of excess weight were derived. Data from over 23,000 patients with breast and colorectal cancer were subsequently analyzed using time-to-event models for death with the date of diagnosis as start of follow-up. Study-specific results were combined through a random effect meta-analysis.
RESULTS
We found a significant dose-response relationship (
CONCLUSIONS
Excess body fatness during early to mid-adulthood is associated not only with an increased risk of developing cancer, but also with a lower survival in patients with breast cancer.
IMPACT
Our results emphasize the importance of public health policies aimed at reducing overweight during adulthood and inform future studies on the relationship between excess weight and cancer outcomes.
Identifiants
pubmed: 34782393
pii: 1055-9965.EPI-21-0688
doi: 10.1158/1055-9965.EPI-21-0688
pmc: PMC7612347
mid: EMS139796
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-333Subventions
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : British Heart Foundation
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C864/A14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A29017
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Commentaires et corrections
Type : CommentOn
Informations de copyright
©2021 American Association for Cancer Research.
Références
Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
Cancer Res. 2008 Dec 15;68(24):10238-46
pubmed: 19074892
Int J Cancer. 2011 Sep 1;129(5):1214-24
pubmed: 21064092
PLoS Med. 2016 Aug 16;13(8):e1002081
pubmed: 27529652
Respir Investig. 2019 Jul;57(4):376-379
pubmed: 30770232
Cancer. 2002 May 1;94(9):2490-501
pubmed: 12015775
Int J Cancer. 2010 Jan 15;126(2):490-9
pubmed: 19585578
N Engl J Med. 2010 Dec 2;363(23):2211-9
pubmed: 21121834
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1244-59
pubmed: 22695735
BMC Med. 2020 Jan 10;18(1):5
pubmed: 31918762
Stat Med. 1992 Oct-Nov;11(14-15):1871-9
pubmed: 1480879
BMJ. 2010 Feb 05;340:c221
pubmed: 20139215
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
PLoS Med. 2019 Dec 23;16(12):e1002989
pubmed: 31869400
NPJ Breast Cancer. 2019 Oct 2;5:33
pubmed: 31602394
Br J Cancer. 2003 Aug 4;89(3):431-6
pubmed: 12888808
Lancet Infect Dis. 2006 Jul;6(7):438-46
pubmed: 16790384
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Clin Oncol (R Coll Radiol). 2020 Sep;32(9):591-608
pubmed: 32595101
Cancer Epidemiol. 2016 Apr;41:8-15
pubmed: 26775081
J Clin Oncol. 2012 Jan 10;30(2):164-71
pubmed: 22162568
Eur J Epidemiol. 2016 Sep;31(9):893-904
pubmed: 27300353
J Natl Cancer Inst. 2018 Mar 1;110(3):232-240
pubmed: 29933439
Breast Cancer Res Treat. 2010 Oct;123(3):627-35
pubmed: 20571870
Jpn J Clin Oncol. 2014 Sep;44(9):777-82
pubmed: 25104790
Int J Obes Relat Metab Disord. 2002 Jun;26(6):789-96
pubmed: 12037649
Metabolism. 2019 Mar;92:6-10
pubmed: 30253139
Gynecol Oncol. 2015 Jul;138(1):201-6
pubmed: 25870918
BMC Med Res Methodol. 2009 Jul 28;9:57
pubmed: 19638200
Br J Cancer. 2017 May 23;116(11):1486-1497
pubmed: 28441380
Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1518-1524
pubmed: 31201224
BMJ Open. 2014 Sep 17;4(9):e005629
pubmed: 25231490
Stat Med. 2012 Dec 20;31(29):3821-39
pubmed: 22807043
Int J Methods Psychiatr Res. 2011 Mar;20(1):40-9
pubmed: 21499542
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Ann Oncol. 2014 Feb;25(2):519-24
pubmed: 24412821
Int J Cancer. 2020 Aug 1;147(3):793-802
pubmed: 31755107
Tech Coloproctol. 2016 Aug;20(8):517-35
pubmed: 27343117
Stat Med. 2013 Nov 20;32(26):4499-514
pubmed: 23703895
Int J Epidemiol. 2011 Aug;40(4):985-96
pubmed: 21357186
Lancet. 2016 Aug 20;388(10046):776-86
pubmed: 27423262
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
J Clin Oncol. 2009 Jan 10;27(2):176-85
pubmed: 19064975
Ann Oncol. 2012 Feb;23(2):479-90
pubmed: 21597097
Int J Epidemiol. 2017 Apr 1;46(2):e8
pubmed: 26066328
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404